drugset / Trial / NCT02640508
Eribulin and Lenvatinib in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
Timeline
- Start
- 2016-05
- Primary completion
- 2020-11-24
- Completion
- 2023-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Lenvatinib | Small molecule | 24 mg | Oral |